MUMBAI (Maharashtra): A groundbreaking interim report on a clinical trial being conducted in three hospitals has shown that Covid-19 patients on natural treatment are resolving most symptoms earlier than those on conventional medicines. The interim report on a combination treatment of an Ayurvedic remedy called ‘Immunofree’ by Corival Life Sciences, and Nutraceutical called ‘Reginmune’ by Biogetica have shown exceptional results as against the present government SOP of conventional medicines for coronavirus treatment.
When compared with conventional treatments for COVID-19, Ayurvedic treatment has shown quicker improvement too. 86.66 per cent of patients undergoing a natural treatment tested negative by the fifth day vs 60 per cent patients on conventional treatment.
On the 10th day, all patients tested negative for the virus after Ayurvedic treatment.
Furthermore, numerous tests such as C reactive protein, Procalcitonin, D Dimer and RT-PCR for novel coronavirus are also showing 20 to 60 per cent better improvement for the natural treatment, when compared to conventional treatment.
Numerous subjective endpoints such as body pain and fatigue are also leaning towards natural treatment. Both Clinician’s Global Assessment of Symptoms and Subject’s Global Assessment of Symptoms clearly showed improvements on both arms showing more significant data in the test group.
The three hospitals where Ayurvedic clinical trials are taking place in India are Government Medical Hospital, Srikakulam Andhra Pradesh; Parul Sevashram Hospital, Vadodara, Gujarat, and Lokmanya Hospital Pune, Maharashtra.
The conventional treatment in use depends on the severity of the patient and includes HCQ, Azithromycin, Favipiravir and Cetirizine. This trial also has broader inclusion criteria than others conducted on natural medicine as it includes patients up to 70 years old, with low oxygen saturation and co-morbidities.
It is significant to note that none of the patients on the natural treatment progressed past moderate, needed ventilators or had any adverse events. These precedent-setting results have led to accelerated enrolment into this trial and statistically significant results should be ready by month-end.